Do analysts prefer ERNA or GNPX?

Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 508.52%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Ernexa Therapeutics is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ERNA or GNPX more profitable?

Genprex's return on equity of -163.12% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Genprex N/A -163.12% -128.98%

Do analysts rate GNPX or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, GNPX or XCUR?

Exicure has higher revenue and earnings than Genprex. Exicure is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A Exicure $500K 15.59 -$4.95M -$1.32 N/A

Is GNPX or XCUR more profitable?

Genprex's return on equity of -163.12% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% Exicure N/A -237.91% -61.98%

Do analysts recommend GNPX or MTVA?

MetaVia has a consensus price target of $20.00, indicating a potential upside of 1,119.51%. Given MetaVia's stronger consensus rating and higher possible upside, analysts clearly believe MetaVia is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, GNPX or MTVA?

MetaVia is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A MetaVia N/A N/A -$12.97M -$3.23 N/A

Is GNPX or MTVA more profitable?

Genprex's return on equity of -163.12% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% MetaVia N/A -209.67% -107.91%

Do analysts rate GNPX or ALZN?

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Genprex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, GNPX or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A Alzamend Neuro N/A N/A -$8.77M -$2.90 N/A

Is GNPX or ALZN more profitable?

Genprex's return on equity of -163.12% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% Alzamend Neuro N/A -277.74% -200.07%

Do analysts rate AQB or GNPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AQB or GNPX more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets AquaBounty Technologies N/A -147.07% -28.73% Genprex N/A -163.12% -128.98%

Genprex (GNPX) Competitors

$4.00 -0.02 (-0.50%)

Closing price 08/25/2026 04:00 PM Eastern

Extended Trading

$3.97 -0.03 (-0.75%)

As of 08/25/2026 05:31 PM Eastern

Compare

GNPX vs. ERNA, XCUR, MTVA, ALZN, and AQB

Should you buy Genprex stock or one of its competitors? Genprex's main competitors and comparable companies include Ernexa Therapeutics (ERNA), Exicure (XCUR), MetaVia (MTVA), Alzamend Neuro (ALZN), and AquaBounty Technologies (AQB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genprex compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Ernexa Therapeutics and Ernexa Therapeutics both had 2 articles in the media. Genprex's average media sentiment score of 0.52 beat Ernexa Therapeutics' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
Genprex	Positive

Ernexa Therapeutics has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market. Comparatively, Genprex has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ernexa Therapeutics has higher revenue and earnings than Genprex. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	13.86	-$14.08M	-$14.35	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Ernexa Therapeutics presently has a consensus target price of $30.00, indicating a potential upside of 508.52%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Ernexa Therapeutics is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex's return on equity of -163.12% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Genprex	N/A	-163.12%	-128.98%

Summary

Ernexa Therapeutics beats Genprex on 9 of the 13 factors compared between the two stocks.

How does Genprex compare to Exicure?

Genprex (NASDAQ:GNPX) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Genprex has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market. Comparatively, Exicure has a beta of 3.65, indicating that its stock price is 265% more volatile than the broader market.

In the previous week, Genprex and Genprex both had 2 articles in the media. Genprex's average media sentiment score of 0.52 beat Exicure's score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Positive
Exicure	Neutral

14.1% of Genprex shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 0.3% of Genprex shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has higher revenue and earnings than Genprex. Exicure is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
Exicure	$500K	15.59	-$4.95M	-$1.32	N/A

Genprex's return on equity of -163.12% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
Exicure	N/A	-237.91%	-61.98%

Summary

Exicure beats Genprex on 7 of the 10 factors compared between the two stocks.

How does Genprex compare to MetaVia?

Genprex (NASDAQ:GNPX) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

MetaVia is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Genprex's return on equity of -163.12% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
MetaVia	N/A	-209.67%	-107.91%

In the previous week, Genprex had 1 more articles in the media than MetaVia. MarketBeat recorded 2 mentions for Genprex and 1 mentions for MetaVia. Genprex's average media sentiment score of 0.52 beat MetaVia's score of 0.00 indicating that Genprex is being referred to more favorably in the media.

Company	Overall Sentiment
Genprex	Positive
MetaVia	Neutral

Genprex has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

MetaVia has a consensus price target of $20.00, indicating a potential upside of 1,119.51%. Given MetaVia's stronger consensus rating and higher possible upside, analysts clearly believe MetaVia is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

14.1% of Genprex shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

MetaVia beats Genprex on 8 of the 13 factors compared between the two stocks.

How does Genprex compare to Alzamend Neuro?

Genprex (NASDAQ:GNPX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

In the previous week, Alzamend Neuro had 11 more articles in the media than Genprex. MarketBeat recorded 13 mentions for Alzamend Neuro and 2 mentions for Genprex. Alzamend Neuro's average media sentiment score of 0.96 beat Genprex's score of 0.52 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
Genprex	Positive
Alzamend Neuro	Positive

Alzamend Neuro is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
Alzamend Neuro	N/A	N/A	-$8.77M	-$2.90	N/A

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 1,650.00%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Genprex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Genprex's return on equity of -163.12% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
Alzamend Neuro	N/A	-277.74%	-200.07%

14.1% of Genprex shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 0.3% of Genprex shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genprex has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.16, indicating that its share price is 84% less volatile than the broader market.

Summary

Alzamend Neuro beats Genprex on 10 of the 13 factors compared between the two stocks.

How does Genprex compare to AquaBounty Technologies?

AquaBounty Technologies (NASDAQ:AQB) and Genprex (NASDAQ:GNPX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

AquaBounty Technologies' return on equity of -147.07% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AquaBounty Technologies	N/A	-147.07%	-28.73%
Genprex	N/A	-163.12%	-128.98%

Genprex has lower revenue, but higher earnings than AquaBounty Technologies. AquaBounty Technologies is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AquaBounty Technologies	$2.47M	2.77	-$18.49M	-$0.82	N/A
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.9% of AquaBounty Technologies shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 1.0% of AquaBounty Technologies shares are held by company insiders. Comparatively, 0.3% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, AquaBounty Technologies and AquaBounty Technologies both had 2 articles in the media. Genprex's average media sentiment score of 0.52 beat AquaBounty Technologies' score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company	Overall Sentiment
AquaBounty Technologies	Neutral
Genprex	Positive

AquaBounty Technologies has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Genprex has a beta of -0.88, indicating that its stock price is 188% less volatile than the broader market.

Summary

AquaBounty Technologies beats Genprex on 6 of the 10 factors compared between the two stocks.

Get Genprex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNPX vs. The Competition

Export

Metric	Genprex	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.30M	$4.00B	$7.35B	$12.72B
Dividend Yield	N/A	3.63%	2.53%	11.02%
P/E Ratio	-0.03	11.81	270.96	24.14
Price / Sales	N/A	1,381.12	634.76	101.59
Price / Cash	N/A	103.64	78.57	53.12
Price / Book	0.22	16.86	13.14	6.25
Net Income	-$16.23M	-$22.76M	$3.46B	$347.86M
7 Day Performance	0.25%	1.84%	1.52%	0.98%
1 Month Performance	-48.78%	12.26%	8.82%	5.24%
1 Year Performance	-97.85%	57.39%	26.08%	17.04%

Genprex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNPX Genprex	0.4779 of 5 stars	$4.00 -0.5%	N/A	-97.8%	$3.30M	N/A	N/A	20	Upcoming Earnings Short Interest Increase
ERNA Ernexa Therapeutics	1.794 of 5 stars	$4.82 +6.6%	$30.00 +522.4%	-86.2%	$7.86M	$580K	N/A	10	Short Interest Increase
XCUR Exicure	0.593 of 5 stars	$1.18 -9.2%	N/A	-79.9%	$7.73M	$500K	N/A	50	Positive News Short Interest Decrease
MTVA MetaVia	1.6506 of 5 stars	$1.48 +2.8%	$20.00 +1,251.4%	-77.1%	$7.64M	N/A	N/A	8
ALZN Alzamend Neuro	3.4359 of 5 stars	$1.55 -4.9%	$28.00 +1,706.5%	-33.9%	$7.42M	N/A	N/A	4	Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNPX) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genprex (GNPX) Competitors

GNPX vs. ERNA, XCUR, MTVA, ALZN, and AQB

How does Genprex compare to Ernexa Therapeutics?

Summary

How does Genprex compare to Exicure?

Summary

How does Genprex compare to MetaVia?

Summary

How does Genprex compare to Alzamend Neuro?

Summary

How does Genprex compare to AquaBounty Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genprex (GNPX) Competitors

GNPX vs. ERNA, XCUR, MTVA, ALZN, and AQB

How does Genprex compare to Ernexa Therapeutics?

Does the media refer more to ERNA or GNPX?

Which has more volatility & risk, ERNA or GNPX?

Do institutionals and insiders believe in ERNA or GNPX?

Which has higher earnings & valuation, ERNA or GNPX?

Do analysts prefer ERNA or GNPX?

Is ERNA or GNPX more profitable?

Summary

How does Genprex compare to Exicure?

Which has more risk & volatility, GNPX or XCUR?

Does the media prefer GNPX or XCUR?

Do institutionals & insiders believe in GNPX or XCUR?

Do analysts rate GNPX or XCUR?

Which has stronger valuation and earnings, GNPX or XCUR?

Is GNPX or XCUR more profitable?

Summary

How does Genprex compare to MetaVia?

Which has higher valuation and earnings, GNPX or MTVA?

Is GNPX or MTVA more profitable?

Does the media favor GNPX or MTVA?

Which has more risk and volatility, GNPX or MTVA?

Do analysts recommend GNPX or MTVA?

Do institutionals and insiders hold more shares of GNPX or MTVA?

Summary

How does Genprex compare to Alzamend Neuro?

Does the media favor GNPX or ALZN?

Which has stronger valuation and earnings, GNPX or ALZN?

Do analysts rate GNPX or ALZN?

Is GNPX or ALZN more profitable?

Do insiders & institutionals believe in GNPX or ALZN?

Which has more risk and volatility, GNPX or ALZN?

Summary

How does Genprex compare to AquaBounty Technologies?

Is AQB or GNPX more profitable?

Which has higher earnings and valuation, AQB or GNPX?

Do analysts rate AQB or GNPX?

Do institutionals & insiders believe in AQB or GNPX?

Does the media favor AQB or GNPX?

Which has more volatility & risk, AQB or GNPX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNPX vs. The Competition

Genprex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools